Skip to main content
$183.52 -$3.57 (-1.9%)

04:00 PM EDT on 10/22/21

Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX)

CAPS Rating: 4 out of 5

The Company is in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases.

Current Price $183.52 Mkt Cap $47.6B
Open $186.77 P/E Ratio 23.90
Prev. Close $183.52 Div. (Yield) $0.00 (0.0%)
Daily Range $182.88 - $187.15 Volume 1,945,186
52-Wk Range $176.36 - $242.99 Avg. Daily Vol. 1,463,101

Caps

How do you think NASDAQ:VRTX will perform against the market?

Add Stock to CAPS Watchlist

All Players

828 Outperform
70 Underperform
 

All-Star Players

192 Outperform
9 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:VRTX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

CMFJoeFoolery (< 20)
Submitted April 05, 2021

-Bullishness on gene therapy segment and partnership w/ CRISPR-Strength in Cystic Fibrosis treatment (Dominant, but large part of US TAM left to capture)-Research methodology/product development strategy-Current valuation and multiples. ($55Bn,… More

SCOTTRHUETTLCPA (40.35)
Submitted July 22, 2016

9/26/14 DOWN TO UP = <30.04> 7/19/16 = UP TO DOWN

NASDAQ:VRTX VS S&P 500 (SPY)

Fools bullish on NASDAQ:VRTX are also bullish on:

Fools bearish on NASDAQ:VRTX are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about VRTX.

Recs

0
Member Avatar wrciii (87.21) Submitted: 9/20/2021 11:17:23 AM : Outperform Start Price: $187.57 NASDAQ:VRTX Score: -6.28

Salveen

Recs

0
Member Avatar XMFFlygal (99.49) Submitted: 8/23/2021 9:31:56 PM : Outperform Start Price: $231.00 NASDAQ:VRTX Score: -43.68

Product revenues of $1.79 billion, an 18% increase compared to Q2 2020

In the second quarter of 2021, we saw continued, significant growth and strong business performance in our cystic fibrosis franchise. We have now secured reimbursement agreements for the triple combination in more than 15 countries outside the U.S. and started expansion into younger age groups with the U.S. approval in patients 6 to 11 years of age last month. With these advancements, we are poised to reach more patients in 2021 than previously forecasted and are therefore raising our 2021 revenue guidance. Looking forward, we continue to see significant growth ahead in CF, with more than 30,000 CF patients who may benefit from the triple combination but who are not yet treated,

Recs

0
Member Avatar Car12703 (46.82) Submitted: 8/9/2021 10:18:37 AM : Outperform Start Price: $199.83 NASDAQ:VRTX Score: -10.63

From Fidelity August 2021:
Revenue Growth (Last 5 Years) = 43.2%
Revenue % Change (Last Qrtr VS. Same Qrtr Prior Year) = 17.6%
Price/Sales (TTM) = 7.8

Leaderboard

Find the members with the highest scoring picks in VRTX.

Score Leader

dmcnic

dmcnic (61.95) Score: +931.18

The Score Leader is the player with the highest score across all their picks in VRTX.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
bugeyebear 30.94 3/17/2008 Outperform 3Y $14.60 +1,158.63% +269.96% +888.67 0 Comment
lostontheprairie 68.06 3/12/2008 Outperform 5Y $14.99 +1,125.88% +255.79% +870.09 0 Comment
Kudude 60.71 3/12/2008 Outperform 5Y $14.99 +1,125.88% +255.79% +870.09 0 Comment
Salilp 73.84 3/17/2008 Outperform 5Y $15.07 +1,119.38% +273.12% +846.26 0 Comment
davidmouw2 < 20 3/14/2008 Outperform NS $15.43 +1,090.93% +255.69% +835.24 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. snazzysnazz 72.17 3/13/2008 Outperform 5Y $15.49 +1,086.31% +264.38% +821.93 0 Comment
NovaMechanika 20.30 3/20/2008 Outperform 3Y $15.55 +1,081.74% +261.36% +820.38 2 Comments
stnewbie 39.31 3/12/2008 Outperform NS $15.78 +1,064.51% +257.41% +807.10 0 Comment
PrincetonAl 88.75 3/7/2008 Outperform 3Y $15.86 +1,058.64% +264.32% +794.32 1 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. hayrettin 72.70 3/24/2008 Outperform 5Y $16.47 +1,015.73% +252.51% +763.21 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for VRTX.